GSK3-beta activation is a key driver of resistance to RAF inhibition in BRAF mutant melanoma cells

被引：0
|
作者：
Crisan, D. [1 ]
Scharffetter-Kochanek, K. [1 ]
Zhao, F. [2 ]
Paschen, A. [2 ]
Schatz, S. [1 ]
Hainzl, H. [1 ]
Baican, A. [3 ]
Crisan, M. [3 ]
Basu, A. [1 ]
Sindrilaru, A. [1 ]
机构：
[1] Univ Hosp Ulm, Clin Dermatol & Allerg Dis, D-89081 Ulm, Germany
[2] Univ Hosp Essen, Dermatol Clin, Essen, Germany
[3] Univ Clin Cluj Napoca, Clin Dermatol & Venerol, Cluj Napoca, Romania
来源：
EXPERIMENTAL DERMATOLOGY | 2023年 / 32卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P058
引用
收藏
页码：E30 / E30
页数：1
相关论文
共 50 条
  • [41] Quantitative Proteomics Links the Intermediate Filament Nestin to Resistance to Targeted BRAF Inhibition in Melanoma Cells
    Schmitt, Marisa
    Sinnberg, Tobias
    Nalpas, Nicolas C.
    Maass, Annika
    Schittek, Birgit
    Macek, Boris
    MOLECULAR & CELLULAR PROTEOMICS, 2019, 18 (06) : 1096 - 1109
  • [42] Multi-omics analysis delineates resistance mechanisms associated with BRAF inhibition in melanoma cells
    Datta, Keshava K.
    Kore, Hitesh
    Gowda, Harsha
    EXPERIMENTAL CELL RESEARCH, 2024, 442 (01)
  • [43] Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells
    Eszter Molnár
    Dominika Rittler
    Marcell Baranyi
    Michael Grusch
    Walter Berger
    Balázs Döme
    József Tóvári
    Clemens Aigner
    József Tímár
    Tamás Garay
    Balázs Hegedűs
    BMC Cancer, 18
  • [44] Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells
    Molnar, Eszter
    Rittler, Dominika
    Baranyi, Marcell
    Grusch, Michael
    Berger, Walter
    Doeme, Balazs
    Tovari, Jozsef
    Aigner, Clemens
    Timar, Jozsef
    Garay, Tamas
    Hegedus, Balazs
    BMC CANCER, 2018, 18
  • [45] Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation
    Kim, Min Hwan
    Kim, Jongshin
    Hong, Hyowon
    Lee, Si-Hyung
    Lee, June-Koo
    Jung, Eunji
    Kim, Joon
    EMBO JOURNAL, 2016, 35 (05): : 462 - 478
  • [46] Ibrutinib Blocks YAP1 Activation and Reverses BRAF Inhibitor Resistance in Melanoma Cells
    Misek, Sean A.
    Newbury, Patrick A.
    Chekalin, Evgenii
    Paithankar, Shreya
    Doseff, Andrea, I
    Chen, Bin
    Gallo, Kathleen A.
    Neubig, Richard R.
    MOLECULAR PHARMACOLOGY, 2022, 101 (01) : 1 - 12
  • [47] Inhibition of GSK3 promotes replication and survival of pancreatic beta cells
    Mussmann, Rainer
    Geese, Marcus
    Harder, Friedrich
    Kegel, Simone
    Andag, Uwe
    Lomow, Alexander
    Burk, Ulrike
    Onichtchouk, Daria
    Dohrmann, Cord
    Austen, Matthias
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (16) : 12030 - 12037
  • [48] Prenylation Inhibition-Induced Cell Death in Melanoma: Reduced Sensitivity in BRAF Mutant/PTEN Wild-Type Melanoma Cells
    Garay, Tamas
    Kenessey, Istvan
    Molnar, Eszter
    Juhasz, Eva
    Reti, Andrea
    Laszlo, Viktoria
    Rozsas, Anita
    Dobos, Judit
    Doeme, Balazs
    Berger, Walter
    Klepetko, Walter
    Tovari, Jozsef
    Timar, Jozsef
    Hegedus, Balazs
    PLOS ONE, 2015, 10 (02):
  • [49] Single-cell analysis of adaptive resistance and fractional responses of melanoma cells to RAF/MEK inhibition
    Fallahi-Sichani, Mohammad
    Moerke, Nathan J.
    Niepel, Mario
    Zhang, Tnghu
    Gray, Nathanael S.
    Sorger, Peter K.
    CANCER RESEARCH, 2015, 75
  • [50] Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance
    Raaijmakers, Marieke I. G.
    Widmer, Daniel S.
    Narechania, Apurva
    Eichhoff, Ossia
    Freiberger, Sandra N.
    Wenzina, Judith
    Cheng, Phil F.
    Mihic-Probst, Daniela
    Desalle, Rob
    Dummer, Reinhard
    Levesque, Mitchell P.
    ONCOTARGET, 2016, 7 (47) : 77163 - 77174
12345